Fruquintinib in Patients With Metastatic Colorectal Cancer: A Prospective, Multicenter, Observational Study
Latest Information Update: 10 Mar 2025
Price :
$35 *
At a glance
- Drugs Fruquintinib (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms FRUQUENT
- 07 Mar 2025 Status changed from not yet recruiting to recruiting.
- 29 Jan 2025 New trial record